Winkelbauer F W, Schöfl R, Niederle B, Wildling R, Thurnher S, Lammer J
Department of Radiology, University of Vienna, Austria.
AJR Am J Roentgenol. 1996 Jan;166(1):79-84. doi: 10.2214/ajr.166.1.8571911.
The purpose of our study was to evaluate the effectiveness of nitinol stents for palliation of dysphagia due obstructing esophageal cancer, safety of stent placement, and long-term results.
Self-expanding uncoated nitinol stents were inserted either radiologically (14 patients) or endoscopically (12 patients) on an outpatient basis in 26 consecutive patients with dysphagia grade 3 or 4 caused by incurable malignant obstructions in the middle or distal third of the esophagus (n = 22) or at esophagojejunal anastomoses (n = 4). No esophagotracheal fistulas were seen in any patient. In 22 patients prior treatments had failed. Following insertion, the stent lumen was dilated to the maximum diameter. Finally, esophagography or esophagoscopy was done to confirm the position of the stent and patency of the esophageal lumen. Twenty-four hours after the procedure, esophageal function was investigated by a barium swallow. Patients were encouraged to ingest solid food thereafter. Improvement in dysphagia was evaluated 1 week after stent placement and during monthly interviews. Complications were defined as major (aspiration, bleeding, stent misplacement or dislocation, perforation) or minor (reflux esophagitis, chest pain, pharyngeal discomfort). Tumor ingrowth or overgrowth was considered a treatment failure. Twenty-three patients (88%) were followed until death: three patients (12%) were followed for a mean of 14 months.
Exact positioning of the stent and dilation to its maximum diameter were technically feasible in all patients. No stents were placed in the stomach. Patency of the esophageal lumen was successfully restored in 25 patients. In one patient a broken strut of the stent after dilation caused a partial obstruction, which was detected endoscopically. Two patients had recurrent dysphagia due to tumor ingrowth or overgrowth, one after 1 month and the other after 3 months. In these patients an additional overlapping stent was successfully placed. No procedure-related mortalities or major complications occurred. The mean dysphagia grade of 3.5 was improved to a mean grade of 0.6 after stent placement. All patients could take liquids within the first 24 hr. Fifteen patients improved to dysphagia grade 0, seven patients to grade 1, and four patients to grade 2 within 1 week after the procedure. Twenty-three patients (88%) died during the follow-up period (mean survival, 5 months) as a result of their disease. Latest evaluation of the mean dysphagia grade was 0.7. Three patients (12%) are still alive (mean survival, 14 months) with a dysphagia grade 1 in one patient and grade 0 in two.
Implantation of nitinol stents proved to be an effective and safe method of palliating severe dysphagia in patients with obstructing esophageal cancer. The improvement in dysphagia was impressive and long lasting. Placement of the stents was feasible without major procedure-related complications.
本研究旨在评估镍钛合金支架缓解食管癌所致吞咽困难的有效性、支架置入的安全性及长期效果。
26例因食管中、下段(n = 22)或食管空肠吻合口(n = 4)不可治愈的恶性梗阻导致3或4级吞咽困难的患者,在门诊接受了自膨式无涂层镍钛合金支架置入,其中14例经放射学方法置入,12例经内镜方法置入。所有患者均未出现食管气管瘘。22例患者先前治疗失败。支架置入后,将支架内腔扩张至最大直径。最后,行食管造影或食管镜检查以确认支架位置及食管腔通畅情况。术后24小时,通过吞钡检查评估食管功能。此后鼓励患者摄入固体食物。在支架置入1周后及每月随访时评估吞咽困难的改善情况。并发症分为严重(误吸、出血、支架误置或移位、穿孔)或轻微(反流性食管炎、胸痛、咽部不适)。肿瘤向内生长或过度生长被视为治疗失败。23例患者(88%)随访至死亡:3例患者(12%)平均随访14个月。
在所有患者中,将支架精确放置并扩张至最大直径在技术上是可行的。无支架置入胃内。25例患者食管腔通畅得以成功恢复。1例患者扩张后支架支柱断裂导致部分梗阻,经内镜检查发现。2例患者因肿瘤向内生长或过度生长出现吞咽困难复发,1例在1个月后,另1例在3个月后。在这些患者中成功置入了额外的重叠支架。未发生与手术相关的死亡或严重并发症。吞咽困难平均等级从3.5级改善至支架置入后的平均0.6级。所有患者在术后首24小时内均可摄入液体。术后1周内,15例患者吞咽困难改善至0级,7例改善至1级,4例改善至2级。23例患者(88%)在随访期间因疾病死亡(平均生存期5个月)。吞咽困难平均等级的最新评估为0.7级。3例患者(12%)仍存活(平均生存期14个月),其中1例吞咽困难为1级,2例为0级。
镍钛合金支架置入被证明是缓解食管癌梗阻患者严重吞咽困难的一种有效且安全的方法。吞咽困难的改善显著且持久。支架置入可行,未出现与手术相关的严重并发症。